User:Mr. Ibrahem/Granisetron

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Granisetron
Clinical data
Trade namesKytril, Sancuso, others
AHFS/Drugs.comMonograph
MedlinePlusa601211
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth, intravenous, transdermal
Drug class5-HT3 receptor antagonist.[1]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability60%
Protein binding65%
MetabolismLiver
Elimination half-life3–14 hours
ExcretionKidney 11–12%, faecal 38%
Identifiers
  • 1-Methyl-N-((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide
Chemical and physical data
FormulaC18H24N4O
Molar mass312.417 g·mol−1
3D model (JSmol)
  • CN4[C@@H]1CCC[C@H]4C[C@H](C1)NC(=O)c3nn(C)c2ccccc23
  • InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12-,13+,14- checkY
  • Key:MFWNKCLOYSRHCJ-BTTYYORXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Granisetron, sold under the brand name Sancuso among others, is a medication used to treat chemotherapy, radiation, and postoperative nausea and vomiting.[2] It may be taken by mouth, injected into a vein, or used as a skin patch.[2] It is not useful for nausea due to motion sickness or opioids.[4]

Common side effects include headache, constipation, fever, abdominal pain, and heart burn.[3] Other side effects may include allergic reactions.[3] While there is no evidence of harm in pregnancy, such use has not been well studied.[5] It is a 5-HT3 receptor antagonist.[1]

Granisetron was patented in 1985 and approved for medical use in 1991.[6] It is on the World Health Organization's List of Essential Medicines as an alternative to ondansetron.[7] It is available as a generic.[2] In the United Kingdom 10 vials of 1 mg costs the NHS about £20 as of 2021.[2] This amount in the United States costs about 36 USD.[8]

References[edit]

  1. ^ a b "Sancuso". Archived from the original on January 8, 2021. Retrieved December 9, 2021.
  2. ^ a b c d e BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 454. ISBN 978-0857114105.
  3. ^ a b c "Granisetron Monograph for Professionals". Drugs.com. Archived from the original on January 25, 2021. Retrieved December 9, 2021.
  4. ^ Frogge, Margaret Hansen; Goodman, Michelle (April 1999). Cancer Symptom Management. Jones & Bartlett Learning. p. 243. ISBN 978-0-7637-0864-1. Archived from the original on December 11, 2021. Retrieved December 9, 2021.
  5. ^ "Granisetron Use During Pregnancy". Drugs.com. Archived from the original on January 25, 2021. Retrieved December 9, 2021.
  6. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 448. ISBN 9783527607495. Archived from the original on September 30, 2021. Retrieved October 19, 2021.
  7. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  8. ^ "Granisetron Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved December 9, 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Granisetron&oldid=1209064227"